Challenges
Champions Oncology (Nasdaq: CSBR), a US-listed oncology research organisation, had to decide how to enter China: which institutional channels to use, which counterparties were worth meeting and where not to spend effort. The cluster infrastructure and decision-makers that govern commercial entry into Chinese biopharma are not reachable through generic consulting channels.
Approach
SILREAL advised Champions Oncology on China market entry, partner access and government-facing market development. The mandate was led by Managing Director Chenchao Liu. The engagement has ended.
-
Institutional access: Built and activated three government-facilitated channels: Wuxi High-Tech Zone, Suzhou Industrial Park and Minhang (Shanghai) Biopharma Development. They connected Champions Oncology to the cluster infrastructure and decision-makers that govern commercial entry into Chinese biopharma.
-
Programme: Curated and secured a five-region China programme with qualified counterparties.
-
Judgment: Assessed which channels and counterparties were worth pursuing, flagged channel risks before they escalated and advised against options that did not justify the effort.


Result
-
Channels: Three government-facilitated channels built and activated.
-
Meetings: Four completed meetings with clinical-stage biotechs and publicly listed innovators pursuing global development strategies.
-
Selection: A clear view of which doors were worth opening, and which were not.
-
Reference: “Chen is willing to tell us when something is not worth pursuing.” Maria Anna Zipeto, PhD, Executive Vice President, Growth Strategy & Enablement, Champions Oncology

